Immuneering (IMRX) Competitors $3.57 +0.14 (+4.08%) Closing price 04:00 PM EasternExtended Trading$3.51 -0.06 (-1.68%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX vs. ARVN, TSHA, TBPH, SAGE, PRME, RZLT, UPXI, SLDB, KURA, and ORKAShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Arvinas (ARVN), Taysha Gene Therapies (TSHA), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Prime Medicine (PRME), Rezolute (RZLT), Upexi (UPXI), Solid Biosciences (SLDB), Kura Oncology (KURA), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Its Competitors Arvinas Taysha Gene Therapies Theravance Biopharma Sage Therapeutics Prime Medicine Rezolute Upexi Solid Biosciences Kura Oncology Oruka Therapeutics Arvinas (NASDAQ:ARVN) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Do analysts recommend ARVN or IMRX? Arvinas presently has a consensus price target of $20.29, suggesting a potential upside of 166.62%. Immuneering has a consensus price target of $13.25, suggesting a potential upside of 271.15%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Arvinas.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do institutionals and insiders have more ownership in ARVN or IMRX? 95.2% of Arvinas shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 4.7% of Arvinas shares are held by insiders. Comparatively, 22.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, ARVN or IMRX? Arvinas has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Which has stronger valuation & earnings, ARVN or IMRX? Immuneering has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$263.40M2.11-$198.90M-$0.66-11.53Immuneering$320K401.51-$61.04M-$1.96-1.82 Does the media favor ARVN or IMRX? In the previous week, Arvinas had 4 more articles in the media than Immuneering. MarketBeat recorded 5 mentions for Arvinas and 1 mentions for Immuneering. Arvinas' average media sentiment score of 0.50 beat Immuneering's score of 0.00 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ARVN or IMRX more profitable? Immuneering has a net margin of 0.00% compared to Arvinas' net margin of -10.92%. Arvinas' return on equity of -7.74% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-10.92% -7.74% -4.11% Immuneering N/A -119.22%-99.22% SummaryArvinas beats Immuneering on 9 of the 15 factors compared between the two stocks. Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.43M$3.07B$5.59B$9.54BDividend YieldN/A2.41%4.73%4.13%P/E RatioN/A6.2119.1622.30Price / Sales401.51314.01445.9598.89Price / CashN/A42.6035.6858.35Price / Book2.687.828.165.60Net Income-$61.04M-$54.52M$3.25B$265.26M7 Day Performance-2.99%2.07%0.45%-1.00%1 Month Performance5.31%17.29%8.27%6.09%1 Year Performance192.62%14.95%30.29%23.81% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering2.9454 of 5 stars$3.57+4.1%$13.25+271.1%+157.9%$123.43M$320K0.0060ARVNArvinas2.8402 of 5 stars$7.61-2.9%$20.29+166.6%-70.9%$572.25M$263.40M-11.53420Upcoming EarningsTSHATaysha Gene Therapies2.9569 of 5 stars$2.67+0.8%$8.17+205.9%+29.0%$568.85M$7.22M-7.85180News CoveragePositive NewsUpcoming EarningsTBPHTheravance Biopharma2.3056 of 5 stars$11.06+0.3%$16.60+50.1%+16.4%$551.52M$64.38M-9.37110SAGESage Therapeutics3.8315 of 5 stars$8.78-0.2%$8.02-8.7%N/A$551.06M$41.24M-1.51690Earnings ReportAnalyst UpgradePRMEPrime Medicine3.875 of 5 stars$4.09-2.9%$9.25+126.2%-8.2%$550.09M$3.85M-2.00234RZLTRezolute2.1086 of 5 stars$6.38+1.3%$11.83+85.5%+37.2%$548.08MN/A-5.5540UPXIUpexi3.7365 of 5 stars$5.88-3.8%$16.00+172.1%-9.4%$546M$26M0.00130Analyst ForecastSLDBSolid Biosciences3.2346 of 5 stars$7.02+0.3%$15.10+115.1%-13.1%$542.61M$8.09M-2.35100Upcoming EarningsKURAKura Oncology3.25 of 5 stars$6.20-0.5%$24.50+295.2%-67.6%$539.36M$53.88M-2.95130Positive NewsUpcoming EarningsORKAOruka Therapeutics3.021 of 5 stars$14.01-1.7%$40.38+188.2%N/A$533.53MN/A-3.11N/APositive NewsUpcoming Earnings Related Companies and Tools Related Companies ARVN Alternatives TSHA Alternatives TBPH Alternatives SAGE Alternatives PRME Alternatives RZLT Alternatives UPXI Alternatives SLDB Alternatives KURA Alternatives ORKA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRX) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMRX Stock Alerts